Theralase Technologies ( (TSE:TLT) ) has provided an announcement.
Theralase Technologies has announced the successful validation of previous research from the University of Manitoba, demonstrating that Ruvidar is safe and effective in treating the Herpes Simplex Virus, Type 1 (HSV-1) in animal models. This announcement is significant given the global prevalence of HSV-1, which affects an estimated 3.8 billion people under age 50, and the growing HSV treatment market, projected to expand due to increasing concerns over the infection’s spread.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical stage pharmaceutical company that focuses on the research and development of light, radiation, sound, and drug-activated small molecules. Their products are designed for the destruction of cancers, bacteria, and viruses.
YTD Price Performance: -3.57%
Average Trading Volume: 98,063
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$66.9M
For detailed information about TLT stock, go to TipRanks’ Stock Analysis page.